Physician profile
Amr E Elsisi
NPI 1063487296
$3,802.40
in general payments reported to CMS, 2019-2025
14 companies · $930 in 2025
The $930 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $323 · 2021: $69.02 · 2022: $345 · 2023: $726 · 2024: $483 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $706.18 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $527.05 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $458.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $455.21 | 2019-2023 | Xarelto |
| Amgen INC. | $352.15 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $313.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $199.40 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $181.25 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $162.02 | 2019 | |
| Lilly USA, LLC | $133.08 | 2022-2025 | Zepbound |
| Biohaven Pharmaceutical Holding Company Ltd. | $116.10 | 2022 | |
| Amarin Pharma, INC. | $93.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.14 | 2019 | |
| Medtronic USA, INC. | $40.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amr Elsisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.